Autoimmunedisorders are probably the most proliferative field of neurology. It seems like there is a blazing headline every week announcing a new antibody disease. Many of these antibodies are esoteric, but some shake the foundations of medical practice. Anti-MOGantibody is one of those which requires you to stop and pay attention, and it has significantly affected neurological practice in a very big way.
Perhaps the most important thing about anti-MOG antibody disease is that, like the chameleon, it presents in many guises. For the neurologist therefore, the first thing is to recognise these varied manifestations. Here then is a quick list of the 9 manifestations of anti MOG antibody disorder.
This is not something neurologists often come across, but it comes close enough to the specialty. Oral-facial-digital-syndrome is typified by facial deformities, but more importantly, the title makes it clear that it is a syndrome with diverse subtypes. A catchy title for a rare disorder, and this paper reveals all.
Not all catchy titles are convoluted. This one is simple but yet very inspired. It refers to the 2016 Consensus Statement on Concussion in Sport. As for all guidelines, it is all well and good to develop them, but a herculean task to get anyone to take notice. It is therefore very ingenious to use a catchy editorial to do the job.
Another one on amnesia, and what a great title. It is a report of 13 cases of focal retrograde amnesia, all typified by loss of autobiographical memory. The amnesia is severe enough in some cases “to erase the knowledge of their own identity”.
This inspired title clearly took some thinking to conjure. It is on the subject of transthyretin-related amyloidosis (ATTR), a hereditary disorder that equally maims the heart and the brain. Typical features are small fiber neuropathy, autonomic neuropathy, and ventricular hypertrophy. And the treatment, incidentally, requires transplanting a third organ, the liver.
Now here is a title to pique anyone’s neurological curiosity. It is about a peculiar disorder, parakinesia brachialis oscitans. There is really no cat to be let out of the bag here; the paper’s abstract reveals all. In some cases of hemiplegia, the abstract says, “yawning is associated with involuntary raising of the paralysed arm”. Read all about it!
This simple but catchy title is an excellent play on words. It is clearly about the contrariness of the acts of sleep and waking in one headline. This editorial is more than just a catchy title; it is a strong call to action!
It takes great imagination to come up with a title that contains burnout, embers and kindling. And the result is catchy. Burnout is a serious issue that threatens neurological practice, and this editorial flags the concern very forcefully: “the message for all is clear: medicine must identify the root causes of burnout, and more importantly, put the joy back in medicine“. It is time to see the light!
Probably not the catchiest title one could come up with, but it is catchy enough to attract attention. The title refers to fingolimod, the multiple sclerosis drug which predisposes to treatment-resistant warts. Simple verruca is bad enough, but the human papilloma virus (HPV) which causes it happens to trigger more sinister diseases: cervical and anogenital cancer. Therefore, with fingolimod, we must pay attention to warts and all!
Do you have any catchy titles up your sleeves? Do leave a comment.
Multiple sclerosis (MS) takes a large chunk of neurological practice. This is not only because it is common, but also because of its devastating impact. It predominantly affects the young, and deals a blow that reverberates through the wider family and society. This is why it is a top priority in neurology.
A lot however remains uncertain and controversial in MS. The cause of MS for instance remains unknown although the list of risk factors is a mile long (see my previous blog listing the top 6 MS risk factors). MS is a well-known condition but it features prominently in the most controversial questions in neurology. The pathology and subtypes of MS are subjects of intense debate, and the best tests and treatments are still being worked out.
But it’s not all controversy and conflict in the world of MS. There is real progress shining a light to a brighter future in MS ,and here are a 11 I have found.
1. Interferons, with twists
Interferons have been the mainstay of MS treatment for decades. They are still standing their grounds despite inconclusive evidence of their effectiveness, their side effects, and the challenge from newer treatments. One way they hope to carry on into the future is by joining forces with oral contraceptives. This is according to a paper published in Neurology last year titled Oral contraceptives combined with interferon β in multiple sclerosis. The authors report that ethinylstradiol and desogestrel aid interferon-ß to reduce the number of new lesions in women with relapsing remitting multiple sclerosis.
In what may be an attempt at rehabilitation, H pyloriis attempting to make a good name for itself. Notorius for causing stomach ulcers, it now wants to be known as the patron saint of MS. It is a tenuous link I have to say, but I can’t argue against the research paper published in the prestigious Journal of Neurology, Neurosurgery and Psychiatry (JNNP). The article has a refreshingly self-explanatory title Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females. The authors show that people with MS are less likely to be infected with H. pylori than control subjects. But I will not rush to swim in that dirty-looking pool yet, the margin is thin; 16% versus 21% in control subjects. It however raises the intriguing relationship between infections and autoimmunity, a subject explored brilliantly in the accompanying editorial, the hygiene hypothesis of multiple sclerosis.
Phenytoin is very familiar to neurologists because it was a leading epilepsy medication for decades. Although it still has pride of place in the treatment of status epilepsy, it has largely fallen out of favour-mainly for its cosmetic and cognitive side effects. It is therefore surprising to see phenytoin resurrecting in the world of multiple sclerosis. In a large trial published in Lancet Neurology this year, researchers showed a neuroprotective effect of phenytoin on optic neuritis, a common symptom of MS. Neuroprotection, if you must know, is the holy grail of neurology. The article is titled Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. But you might as well read the distilled, and not over-sensational title, in The Telegraph, Cheap epilepsy drug could prevent nerve damage in Multiple Sclerosis. I think the findings require a long stretch of the imagination, but I am happy to do this to remain positive.
Ozanimod is a sphingosine-1-phosphate receptor modulator, and it has shown promise in trials of relapsing remitting MS. This was the conclusion of a recent randomised, placebo-controlled, phase 2 trial of Ozanimod in MS published in Lancet Neurology. Heart-warmingly called the RADIANCE study, the authors demonstrated the effectiveness of Ozanimod in subjects across 55 centres spread over 13 countries. This feat was rewarded with demonstrable reduction in MRI lesion load in the treated subjects. The phase 3 trial therefore promises a lot…but will it deliver?
8. Anoctamin 2 (ANO2)
Researchers are veritable hunters, looking for weak spots in their prey, diseases. They then hone in on their victims vulnerabilities, and pounce. In this way they develop treatment strategies. One such weak spot, recently reported in Proceedings of the National Academy of Sciences (PNAS), is connected to the chloride channel protein Anoctamin 2 (ANO2). The paper, Anoctamin 2 identified as an autoimmune target in multiple sclerosis, reports that subjects with MS have high antibody activity against ANO2. It’s rather complex biochemistry, and for a digested read see the version in Multiple Sclerosis News Today titled New Protein, Anoctamin 2, Identified as a Target of Autoantibody Production in MS. If ANO2 has anything to do with causing MS, you can be sure treatment strategies will follow. If this turns out to be an important pathway in MS, the armoury of MSologists will soon contain stronger firepower.
MS is as much a neurological, as it is a radiological, condition. The diagnosis of MS is heavily reliant on what is, or is not, a lesion on MRI scans; what is new and what is old; and what is getting bigger or smaller. Believe me, this is hardly ever straightforward. It is therefore gratifying to read an article (OK, I admit it, an abstract) in the American Journal of Neuroradiology titled FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection. The authors report that they greatly improved the detection of MS lesions by combining two standard magnetic resonance imaging (MRI) techniques called T2 and FLAIR. This technique, FLAIR2, the authors say, is ‘a simple approach of obtaining CSF suppression with an improved contrast-to-noise ratio’, whatever that means! It does make one worry- how much we are actually missing now? FLAIR2 to the rescue.